General anesthetic combination

5 marketed 2 in Phase 3

This page covers all General anesthetic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine), Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane), Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane).

Targets

Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine) · Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane) · Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane) · GABA-A receptor · NMDA receptor antagonist (ketamine) and GABA-A receptor agonist (propofol)

Marketed (5)

Phase 3 pipeline (2)